CD274 and breast cancer: mLOY could promote immune evasion by disrupting the T cell function and upregulating the expression of immune checkpoint molecules, such as CD274, LAG3, and HAVCR2, resulting in T cell exhaustion and increased susceptibility to PD-1-targeted immunotherapy which is an essential treatment for BC [117, 130].